Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome.
We determined the effects of combined sotalol (160 mg/day) and flecainide (200 mg/day) in 15 patients with the Wolff-Parkinson-White syndrome. After medication given for 3 days, the plasma levels were 0.8 +/- 0.3 micrograms/ml for sotalol and 232 +/- 104 ng/ml for flecainide. Electrophysiologic testing showed complete blockade of the accessory pathway in 4 patients and a decrease in the anterograde conduction capacity by 27% in the remainder. The effect on the accessory pathway was unrelated to the resting conduction properties. Initiation of circus movement tachycardia was prevented in 5 of 11 patients. During a median period of 28 months of follow-up, 87% of patients were either free of tachycardia or satisfactorily improved. No proarrhythmic or adverse drug effects were observed.
Gössinger
H D
HD
First Department of Medicine, University of Vienna, Austria.
Siostrzonek
P
P
Mösslacher
H
H
D000328:Adult; D004338:Drug Combinations; D005260:Female; D005424:Flecainide / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D012032:Refractory Period, Electrophysiological / Q000187:drug effects; D013015:Sotalol / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D014927:Wolff-Parkinson-White Syndrome / Q000097:blood / Q000188:drug therapy*
D004338:Drug Combinations; D013015:Sotalol; D005424:Flecainide